- Home
- SFWL vs IOBT Comparison
SFWL vs IOBT Comparison
Compare SFWL & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFWL
- IOBT
- Stock Information
- Founded
- SFWL 2001
- IOBT 2014
- Country
- SFWL China
- IOBT Denmark
- Employees
- SFWL N/A
- IOBT N/A
- Industry
- SFWL Trucking Freight/Courier Services
- IOBT Biotechnology: Pharmaceutical Preparations
- Sector
- SFWL Industrials
- IOBT Health Care
- Exchange
- SFWL Nasdaq
- IOBT Nasdaq
- Market Cap
- SFWL 82.3M
- IOBT 91.6M
- IPO Year
- SFWL 2023
- IOBT 2021
- Fundamental
- Price
- SFWL $0.99
- IOBT $2.22
- Analyst Decision
- SFWL
- IOBT Strong Buy
- Analyst Count
- SFWL 0
- IOBT 3
- Target Price
- SFWL N/A
- IOBT $9.33
- AVG Volume (30 Days)
- SFWL 13.0K
- IOBT 575.9K
- Earning Date
- SFWL 09-04-2025
- IOBT 08-12-2025
- Dividend Yield
- SFWL N/A
- IOBT N/A
- EPS Growth
- SFWL 4.79
- IOBT N/A
- EPS
- SFWL 0.13
- IOBT N/A
- Revenue
- SFWL $504,158,000.00
- IOBT N/A
- Revenue This Year
- SFWL N/A
- IOBT N/A
- Revenue Next Year
- SFWL N/A
- IOBT N/A
- P/E Ratio
- SFWL $7.48
- IOBT N/A
- Revenue Growth
- SFWL 24.75
- IOBT N/A
- 52 Week Low
- SFWL $0.86
- IOBT $0.66
- 52 Week High
- SFWL $1.60
- IOBT $2.48
- Technical
- Relative Strength Index (RSI)
- SFWL 51.50
- IOBT 66.72
- Support Level
- SFWL $0.95
- IOBT $2.06
- Resistance Level
- SFWL $1.02
- IOBT $2.48
- Average True Range (ATR)
- SFWL 0.03
- IOBT 0.23
- MACD
- SFWL 0.00
- IOBT 0.02
- Stochastic Oscillator
- SFWL 72.80
- IOBT 68.92
About SFWL Shengfeng Development Limited
Shengfeng Development Ltd is a holding company. Through its subsidiaries, it offers contract logistics services in China. The contract logistics services offered by the company include planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services.
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.